New research indicates that the composition of the human gut microbiome may influence how patients respond to cancer immunotherapy, however, the mechanisms through which the microbiota alter immunotherapy efficacy remain unclear. Join Rachel Newsome as she reveals how the enrichment of Bacteroides in the microbiota was associated with an improved response to immune checkpoint inhibition treatment. By studying the supernatants of cultured, clinically-derived Bacteroides isolates, an immunostimulatory 6-strain consortium was developed with potent anti-tumor synergy with immunotherapy. Furthermore, a novel metabolite was discovered in the supernatant of these isolates that increased stimulation of anti-tumor cytokine production and decreased tumor growth in a mouse model of non-small cell lung cancer (NSCLC).
In this webinar, take a deep dive into how high-throughput microbial isolation and cultivation accelerates insights into the effects of the microbiota on cancer immunotherapy, and learn why live isolate libraries are critical for functional studies, metabolite discovery, and microbiome-based drug development.
Rachel C. Newsome, PhD.
Dr. Christian Jobin lab, University of Florida
Rachel Newsome’s undergraduate research was done in the lab of Dr. Steven Bruner in the Department of Chemistry at the University of Florida, investigating the natural product biosynthesis of the colibactin pks gene cluster in E. coli, specifically focusing on the mechanistic enzymology of the multidrug and toxic compound extrusion protein ClbM. Rachel worked in Dr. Christian Jobin’s lab as a lab technician from 2016 to 2018 and started as a graduate student in the Graduate Program in Biomedical Sciences in the Fall of 2018 in the advanced concentrations of Cancer Biology and Clinical and Translational Science. Her graduate research focuses on the role of the gut microbiota in cancer immunotherapy. Rachel uses specific pathogen-free and germ-free mouse and zebrafish models of cancer and inflammation, bacterial culturomics, flow cytometry, primary cell culture, histology/pathology, next-generation sequencing, and immune checkpoint therapies to dissect the role of specific bacterial products in driving anti-tumor synergy with anti-PD-1 therapy.